Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 16, 2026

ZenaTech completa su 25.ª adquisición con la canadiense Velocity Geomatics Inc., con sede en Alberta, expandiendo Drones como Servicio hacia los servicios ambientales y regulatorios en el sector del petróleo y el gas

View original at globenewswire.com
ZenaTech completa su 25.ª adquisición con la canadiense Velocity Geomatics Inc., con sede en Alberta, expandiendo Drones como Servicio hacia los servicios ambientales y regulatorios en el sector del petróleo y el gas VANCOUVER, Columbia Británica, July 16, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Velocity Group brings a solid client base, strong regional expertise, and a long track record supporting drone-based surveying and geomatics projects, including for some of the largest multinational oil and gas producers; there is a significant opportunity to enhance these services with AI-driven drone technology for surveying, mapping, inspection, and infrastructure monitoring.

    60% confidence

  • The Velocity Geomatics acquisition expands ZenaTech's DaaS business into the Canadian oil and gas sector, focusing on environmental and regulatory assessments, and fulfills the goal announced at its 2024 public offering of completing 25 acquisitions to support the DaaS business; the company expects to set new benchmarks in the near term.

    60% confidence

Data points we hold from this source

ZenaTech, Inc. · acquisition count25 acquisitions
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com